Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Apr 25;17(4):e0264894. doi: 10.1371/journal.pone.0264894

Intra-atrial activation pattern is useful to localize the areas of non-pulmonary vein triggers of atrial fibrillation

Kazuo Sakamoto 1,#, Yasushi Mukai 1,2,*,#, Shunsuke Kawai 1,2, Kazuhiro Nagaoka 3, Shujiro Inoue 4, Susumu Takase 1, Daisuke Yakabe 1,5, Shota Ikeda 1, Hiroshi Mannoji 6, Tomomi Nagayama 1, Akiko Chishaki 7, Hiroyuki Tsutsui 1
Editor: Luigi Sciarra8
PMCID: PMC9037930  PMID: 35468171

Abstract

Background

Pulmonary vein isolation (PVI) is an established ablation procedure for atrial fibrillation (AF), however, PVI alone is insufficient to suppress AF recurrence. Non-pulmonary vein (non-PV) trigger ablation is one of the promising strategies beyond PVI and has been shown to be effective in refractory/persistent AF cases. To make non-PV trigger ablation more standardized, it is essential to develop a simple method to localize the origin of non-PV triggers.

Methods

We retrospectively analyzed 37 non-PV triggers in 751 ablation sessions for symptomatic AF from January 2017 to December 2020. Regarding non-PV triggers, intra-atrial activation interval from the earliest in right atrium (RA) to proximal coronary sinus (CS) (RA-CSp) and that from the earliest in RA to distal CS (RA-CSd) obtained by a basically-positioned duodecapolar RA-CS catheter were compared among 3 originating non-PV areas [RA, atrial septum (SEP) and left atrium (LA)].

Results

RA-CSp of RA non-PV trigger (56.4 ± 23.4 ms) was significantly longer than that of SEP non-PV (14.8 ± 25.6 ms, p = 0.019) and LA non-PV (-24.9 ± 27.9 ms, p = 0.0004). RA-CSd of RA non-PV (75.9 ± 32.1 ms) was significantly longer than that of SEP non-PV (34.2 ± 32.6 ms, p = 0.040) and LA non-PV (-13.3 ± 41.2 ms, p = 0.0008). RA-CSp and RA-CSd of SEP non-PV were significantly longer than those of LA non-PV (p = 0.022 and p = 0.016, respectively). Sensitivity and specificity of an algorithm to differentiate the area of non-PV trigger using RA-CSp (cut-off value: 50 ms) and RA-CSd (cut-off value: 0 ms) were 88% and 97% for RA non-PV, 81% and 73% for SEP non-PV, 65% and 95% for LA non-PV, respectively.

Conclusions

The analysis of intra-atrial activation sequences was useful to differentiate non-PV trigger areas. A simple algorithm to localize the area of non-PV trigger would be helpful to identify non-PV trigger sites in AF ablation.

Introduction

Pulmonary vein isolation (PVI) is an established ablation procedure for atrial fibrillation (AF), however, PVI alone is insufficient to suppress recurrences of AF [14]. In order to achieve better outcomes, additional ablation procedures beyond PVI have been explored [5]. Several ablation procedures such as left atrial posterior wall isolation, linear ablation, ganglionated plexus ablation, complex fractionated atrial electrogram (CFAE) ablation, low voltage area (LVA) ablation and non-pulmonary vein (non-PV) trigger ablation have been reported to be effective, however, none of them have become an established procedure beyond PVI so far [610]. While linear-based ablations including posterior wall isolation are uniform procedures, CFAE ablation, LVA ablation and non-PV trigger ablation may be unique treatments for each patient. Recently, it has been reported that elimination of non-PV triggers is related to favorable outcomes in persistent AF as well as in paroxysmal AF [1115]. Although the impact of non-PV triggers in AF has become more evident, non-PV trigger ablation has not been standardized as an additional procedure to PVI, partly because of the need of skilled catheter technique of non-PV trigger mapping [16].

The aim of this study was to compare intra-atrial activation sequences of non-PV triggers from different areas of the atria, and to establish simple criteria for localizing the areas of non-PV triggers using basic electrodes positioned by default.

Methods

Patient population

We retrospectively analyzed 37 non-PV triggers in 751 ablation sessions for symptomatic AF (including 310 paroxysmal AF) from January 2017 to December 2020. This study was in compliance with the principles outlined in the Declaration of Helsinki and was approved by the institutional review board for ethics at our institution, Kyushu University Hospital (approval no. 29–44). Informed consent was obtained in the form of opt-out on the web-site (https://www.cardiol.med.kyushu-u.ac.jp/research/clinical-research/).

Electrophysiological study and ablation of non-PV trigger

Antiarrhythmic drugs were discontinued at least five half-lives before AF ablation. All patients underwent electrophysiological study (EPS) and catheter ablation under deep sedation and fasting conditions. ​A 20-pole catheter (BeeAT, Japan Lifeline, Tokyo, Japan) was inserted via right jugular vein, and the proximal portion of the catheter was placed along the superior vena cava (SVC) and crista terminalis (CT) and the distal portion was located in the coronary sinus (CS) (Fig 1A). Another 10-pole catheter was inserted for right ventricular pacing. Following trans-septal puncture under guidance of intra-cardiac echocardiography (5.5 ~ 10 MHz, 8 Fr, AcuNav, Biosense Webster, Diamond Bar, CA), two long sheaths (SL1, AF Division, Abbott/St. Jude Medical, Minneapolis, MN, USA) were introduced into left atrium (LA). We used CARTO system (Biosense Webster, Diamond Bar, CA, USA) or Ensite system (Abbott, St. Paul, MN, USA) with catheters corresponding to either 3D mapping system. That is, CARTO system used Lasso, PENTARAY Nav catheter and Navistar THERMOCOOL (Biosense Webster, Diamond Bar, CA, USA), while Ensite system used a 20-pole circular catheter, HD Grid and TactiCath (Abbott, St. Paul, MN, USA).

Fig 1. Catheter position and intra-cardiac electrograms of AF initiation by a non-PV trigger.

Fig 1

A, basically-positioned RA-CS catheter and RV catheter in front view (a) and LAO (b). B, Surface electrocardiograms and intra-cardiac electrograms of AF initiation by a non-PV trigger (a) and focused intra-cardiac electrograms of the premature atrial beat of a non-PV trigger indicating intra-cardiac activation intervals analyzed in the present study (b). RA-CSp and RA-CSd are the intra-atrial activation interval from the earliest in RA to proximal CS and that from the earliest in RA to distal CS, respectively. RA, right atrium; CS, coronary sinus; RV, right ventricle; LAO, left anterior oblique; SVC, superior vena cava.

Regardless of the first or multiple sessions, we completed extended PVI. After completion of PVI, we performed non-PV trigger induction test in all sessions. The induction and identification methods were as follows. When spontaneous AF initiation was not observed, we tried to induce AF in one or both the following ways: (1) induction with a bolus injection of isoproterenol (3–5 μg) and adenosine (20 mg) [15]. If not induced, we induced AF by atrial burst pacing (30-beat at an amplitude of 10V and pulse width of 1 ms from the ostium of CS; increasing from 240 to 320 ppm in steps of 20 ppm) with a bolus injection of isoproterenol (3–5 μg). Then, we conducted intra-cardiac cardioversion (10–30 J) with BeeAT and restored AF to sinus rhythm. After termination of AF, we observed if AF was spontaneously initiated for a few minutes. Once AF was initiated, we focused on the premature atrial beat (PAB) that initiated AF and we defined the PAB as a non-PV trigger. Multipolar mapping catheters (PENTARAY Nav/HD Grid and circular catheters) were repositioned to the originating area of the non-PV trigger according to the intra-atrial activation sequences. Again, the trigger PAB was mapped and localized regarding the prematurity of electrograms recorded in the multipolar mapping catheters [17, 18]. When the prematurity was confined in the mapping catheters, we ablated the earliest point as the origin of AF trigger. Finally, the localization of the non-PV trigger was confirmed when the PAB initiating AF was eliminated after ablation using the aforementioned induction protocol. AF induction test was repeated to see if there were any other non-PV triggers remaining.

Analysis of intra-atrial activation pattern of non-PV trigger

Non-PV triggers that appeared three times or more were analyzed and triggers from SVC were excluded. Intra-atrial activation interval from the earliest in right atrium (RA) to proximal CS (RA-CSp) and that from the earliest in RA to distal CS (RA-CSd) in a BeeAT catheter were measured in each non-PV trigger. The earliest in RA was defined as the first deflection from baseline in RA electrodes (Fig 1B). Both RA-CSp and RA-CSd for each trigger were averaged over a series of initiations.

RA-CSp and RA-CSd were compared among three originating areas of non-PV triggers; RA, atrial septum (SEP) and LA. Diagnostic thresholds of RA-CSp and RA-CSd were calculated to distinguish the three areas (RA, SEP and LA) in the following ways. Finally, a simple algorithm to differentiate the areas of the origins was created by combining the calculated thresholds of RA-CSp and RA-CSd.

Statistical analysis

The data are expressed as mean ± standard deviation (SD) for continuous variables, and numbers and percentages for categorical variables. A comparison of continuous variables and categorical variables between pairs of groups was carried out using the Kruskal–Wallis test with the Steel–Dwass post hoc test and the chi-square test or Fisher’s exact test, appropriately. The thresholds of RA-CSp and RA-CSd were determined based on the area under the curve (AUC) of the receiver operating characteristic (ROC) curve. Moreover, the sensitivity and specificity of the algorithm differentiating non-PV triggers were verified. JMP software (Ver. 15, SAS institute Inc., NC, USA) was used for all statistical analyses. The significance of the comparison between groups was defined as p < 0.05.

Results

Patient characteristics and catheter ablation

Patient characteristics of 35 patients with 37 non-PV triggers are shown in Table 1. Mean age was 65.7 ± 10.1 years, and 25 (71%) were male. Twelve sessions were first sessions while 23 sessions were of multiple sessions. There were 17 sessions (49%) with paroxysmal and 18 sessions (51%) with persistent AF. Five out of 35 sessions had undergone cavotricuspid isthmus (CTI) block line in previous sessions. Left ventricular ejection fraction was 64.9 ± 8.1% and left atrial dimension was 41.9 ± 6.8 mm. The mean CHADS2 score was 1.1±1.1. Number of studied non-PV triggers in RA, SEP and LA were 8, 11 and 16, respectively. There were no significant differences in patient characteristics among the three areas. We considered supraventricular tachycardias (SVT) as possible triggers of AF as well [19]. CTI-dependent atrial flutters were induced during EPS in 3 cases, but no other SVTs were induced in the studied patients.

Table 1. Patient characteristics.

Variable All (n = 35) RA (n = 8) SEP (n = 11) LA (n = 16) P value
Age (years) mean±SD 65.7±10.1 67.1±4.1 63.1±9.5 66.7±12.4 0.486
Male, n (%) 25 (71) 5(63) 9 (81) 11(69) 0.610
PAF, n (%) 17 (49) 5 (63) 4 (36) 8 (50) 0.521
Multi-sessions, n (%) 23 (66) 4 (50) 3 (27) 5 (31) 0.563
Previous CTI block line, n (%) 5 (14) 0 (0) 2 (18) 3 (19) 0.421
LVEF (%) mean±SD 64.9±8.1 65.6±4.7 63.8±10.6 65.4±7.9 0.940
LAD (%) mean±SD 41.9±6.8 43.4±7.6 39.2±8.4 43.1±4.7 0.561
Hypertension, n (%) 22 (63) 5 (63) 9 (82) 8 (50) 0.225
Diabetes mellitus, n (%) 4 (11) 1 (13) 1 (9) 2 (13) 0.956
Heart failure, n (%) 5 (14) 1 (13) 3 (27) 1 (6) 0.315
Stroke, n (%) 2 (6) 1 (13) 0 (0) 1 (6) 0.402
CHADS2 (points) mean±SD 1.1±1.1 1.1±1.2 1.2±0.8 1.1±1.3 0.856

RA, right atrium; SEP, atrial septum; LA, left atrium; PAF, paroxysmal atrial fibrillation; CTI, cavotricuspid isthmus; LVEF, left ventricular ejection fraction; LAD, left atrial diameter

The 37 non-PV triggers were successfully mapped and eliminated after 5.5 ± 2.5 times of induction and 4.4±3.5 times of cardioversion. There were no significant differences among three areas regarding these numbers of times (Table 2).

Table 2. Incidences of non-PV trigger firing and the number of cardioversion for AF.

Variable All (n = 37) RA (n = 8) SEP (n = 12) LA (n = 17) P value
The incidence of AF firing 5.5±2.5 4.8±3.1 5.6±3.5 5.8±1.9 0.448
The number of cardioversion for AF 4.4±3.5 3.4±2.1 4.9±4.9 4.5±2.9 0.657

RA, right atrium; SEP, atrial septum; LA, left atrium

Intra-atrial activation interval of non-PV triggers

RA-CSp of RA non-PV trigger was 56.4 ± 23.4 ms, which was longer than that of SEP non-PV trigger (14.8 ± 25.6 ms, p = 0.019) and LA non-PV trigger (-24.9 ± 27.9 ms, p = 0.0004) (Fig 2A). RA-CSd of RA non-PV trigger was 75.9 ± 32.1 ms and was significantly longer than SEP non-PV trigger (34.2 ± 32.6 ms, p = 0.040) and LA non-PV trigger (-13.3 ± 41.2 ms, p = 0.0008) (Fig 2B). RA-CSp of SEP non-PV trigger was significantly longer than that of LA non-PV trigger (p = 0.022) as well as in RA-CSd trigger (p = 0.016).

Fig 2. Comparison of intra-atrial activation intervals of non-PV trigger among RA, SEP and LA.

Fig 2

RA-CSp, intra-atrial activation interval from the earliest in RA to proximal CS; RA-CSd, intra-atrial activation interval from the earliest in RA to distal CS; RA, right atrium; SEP, atrial septum; LA, left atrium; CS, coronary sinus.

Creating an algorithm to localize the area of non-PV trigger

Two ROC curves were created (Fig 3): one is regarding RA-CSp to distinguish RA non-PV trigger from SEP and LA non-PV trigger (A), and the other is RA-CSd to distinguish SEP non-PV trigger from LA non-PV trigger after exclusion of RA non-PV trigger (B). The threshold of RA-CSp was 50 ms with AUC of 0.938 and RA-CSd was 1 ms with AUC of 0.809. Their sensitivity and specificity of RA-CSp were 0.88 and 0.96, and those of RA-CSd were 0.91 and 0.65, respectively.

Fig 3. Receiver operating characteristic curves and cut-off value to distinguish the areas of non-PV trigger.

Fig 3

A. To distinguish RA from SEP and LA with RA-CSp. B, To distinguish SEP from LA with RA-CSd. RA-CSp, intra-atrial activation interval from the earliest in RA to proximal CS; RA-CSd, intra-atrial activation interval from the earliest in RA to distal CS; RA, right atrium; CS, coronary sinus; SEP, atrial septum; LA, left atrium; AUC, area under the curve.

An algorithm to differentiate the area of non-PV trigger was developed by incorporating the two cut-off values of intra-atrial interval; RA-CSp of 50 ms and RA-CSd of 0 ms (Fig 4). Diagnostic accuracy of this algorithm in the present 37 non-PV triggers was validated. Sensitivity and specificity for RA non-PV trigger were 88% and 97%, respectively; for SEP non-PV, 81% and 73%, respectively; for LA non-PV, 65% and 95%, respectively (Table 3).

Fig 4. An algorithm to differentiate the areas of non-PV triggers.

Fig 4

RA-CSp, intra-atrial activation interval from the earliest in RA to proximal CS; RA-CSd, intra-atrial activation interval from the earliest in RA to distal CS; RA, right atrium; SEP, atrial septum; LA, left atrium; CS, coronary sinus.

Table 3. Accuracy of the algorithm to differentiate the area of non-PV triggers.

Sensitivity (%) Specificity (%) PPV (%) NPV (%)
RA 88 97 88 97
SEP 91 73 59 95
LA 65 95 92 76

RA, right atrium; SEP, atrial septum; LA, left atrium; PPV, positive predictive value; NPV, negative predictive value

Discussion

In the present study, it was demonstrated that analyzing intra-atrial activation sequences obtained by a basically-positioned duodecapolar RA-CS catheter was useful to differentiate non-PV trigger area among RA, SEP and LA. We could create a simple algorithm to localize the area of non-PV trigger using intra-atrial activation intervals with an acceptable diagnostic accuracy.

Clinical importance of non-PV trigger mapping and ablation

Several ablation procedures such as linear-based ablations, LVA ablation and non-PV trigger ablation have been explored to achieve the better outcome beyond PVI, however, none of them has become an established procedure beyond PVI. The efficacy of linear-based ablation has been inconsistent among studies, which may be due to the different degree of atrial degeneration and the various mechanisms of AF in every patient [4, 20]. In contrast, non-PV trigger ablation is a unique approach for each patient and could theoretically target every AF initiation [12, 21]. We previously reported that ablation outcome in AF patients with non-PV triggers could be improved to the level of those without non-PV triggers, by selective mapping and ablation of non-PV triggers [15]. For detailed mapping, it is also important to evaluate the substrate such as fibrosis by using multipolar electrodes [22]. Therefore, a standardized mapping strategy for non-PV trigger mapping has been awaited.

The prevalence of non-PV trigger in AF ablation has been reported from 5% to 30%, however, non-PV trigger was detected in 35 among 751 sessions (4.7%) in this study and its rate was lower than the previous studies [12, 23, 24]. This may be related to the different induction manners such as the dose of drugs and the conditions of the patients [2527]. Furthermore, the nonuniform definition of non-PV trigger among studies could be another reason [12, 23, 24]. The present study excluded the trigger in SVC because a PAB from SVC was easily discriminated with the intra-atrial activation pattern [28]. Moreover, PABs that induced AF less than three times and bare PABs that did not initiate AF were also excluded. In terms of the originating area of non-PV triggers, RA, SEP and LA accounted for 22%, 32% and 46%, respectively, and its distribution was similar to previous reports [24, 28]. The detailed localization was CT in 14%, right atrial septum in 16%, left atrial septum in 16%, left atrial posterior wall in 35% and left atrial anterior wall in 5.4%.

The occurrence of non-PV triggers was comparable in paroxysmal (17 in 310, 5.5%) and in non-paroxysmal cases (18 in 441, 4.1%). The Prevalence of non-PV triggers was similar regardless of arrhythmia type, which is consistent to previous reports including ours [15, 24].

The stepwise mapping strategy to identify the non-PV trigger

The mapping procedure of non-PV trigger is a time-consuming and complicated procedure. The stepwise strategy to localize the non-PV trigger includes a general estimation of the non-PV trigger area and a detailed search thereafter. As the first step, we estimated the area of non-PV trigger by intra-atrial activation sequences obtained by a basically-positioned duodecapolar RA-CS catheter. For the second step, we searched for the detailed localization of the trigger using multipolar mapping catheters (PENTARAY Nav / HD Grid) [15, 18]. Our stepwise strategy uncovered and eliminated all the non-PV triggers whereas the initial estimation of non-PV trigger area is important at the beginning. Kubala et al. reported the efficacy of the localization algorithm for non-PV trigger with a combination of surface electrocardiogram and intra-cardiac electrograms, however, interpretation of ectopic P wave morphology was sometimes challenging during AF ablation [29]. On the other hand, intra-atrial activation sequences obtained by a basically-positioned duodecapolar RA-CS catheter in the present study could be easily measured and utilized for estimating non-PV trigger sites. Thus, we aimed to quantitate the activation sequences and validated the predicting accuracy by them.

Intra-atrial activation sequences of non-PV triggers in three different areas

We compared intra-atrial activation sequences of non-PV triggers in three areas including RA, SEP and LA to solve the practical problem of where to place multipolar mapping catheters for detailed localization of the triggers. We found that two intra-atrial activation intervals, RA-CSp and RA-CSd, were different among three areas (Fig 2). A non-PV trigger originating from RA activated RA in prior to CS, that was, RA-CSp and RA-CSd was fully positive. In SEP, RA-CSp could be positive or negative depending on whether the origin was left or right side of atrium. As for LA non-PV trigger, distal CS preceded proximal CS and RA, resulting in a greatly negative in RA-CSd compared to RA-CSp. Thus, differences of the two indices among three areas were reasonable from the perspective of anatomical theory. In addition, recording the local electrograms using a basically-positioned single catheter rather than multiple catheters generalized the inter-electrode distances and made the analysis of intra-atrial activation intervals possible.

We advocated a simple algorithm that could differentiate the areas of non-PV triggers utilizing two indices, RA-CSp and RA-CSd, with sufficient accuracy. This algorithm alone cannot localize the detailed origin of the trigger, however, it may be useful as a preliminary step before a detailed mapping with multipolar catheters. In other words, it could shorten the time of non-PV trigger mapping and could be useful to standardize the technique for non-PV trigger ablation [30].

Limitations

First, this study was a retrospective study analyzing a limited sample size, therefore, a prospective study with more data is needed to standardize this analysis method for clinical practice. Also, the algorithm estimating the area of non-PV trigger needs to be verified using external validation data.

Second, it was uncertain whether all the non-PV triggers were uncovered and eliminated in the real practice. The low incidence in this study of non-PV triggers may be partly because we excluded SVC triggers in this study. Another reason may be because non-PV triggers were induced after completion of PVI in this study. Thus, non-PV triggers originating from near PV antrum might have been eliminated by PVI. Especially, we excluded frequent PABs without AF and PABs that initiated AF less than three times and the amount of non-PV triggers eliminated in this study might be smaller as compared to previous ones.

Third, despite this study with limited cases could not mention the impact of conduction block lines such as CTI block line, lateral mitral isthmus line or LVA block, patients with previous ablation or LVA should be carefully analyzed.

Fourth, the assessment of the intra-cardiac electrograms might be difficult soon after a defibrillation because it takes a few seconds for the baseline of electrograms to return to where it was.

Finally, the electrode catheter used in this study, which can simultaneously record CS and RA potentials (BeeAT), is not available worldwide and can only be used in limited regions. Therefore, it is necessary to verify whether the same results can be obtained using widely available separate CS and RA catheters.

Conclusions

Intra-atrial activation sequences of non-PV triggers obtained by a basically-positioned duodecapolar RA-CS catheter were different among RA, SEP and LA and were useful to estimate the area of non-PV trigger. We proposed a simple algorithm to localize the areas of non-PV triggers, which was accurate and might be helpful to identify non-PV triggers in AF ablation.

Data Availability

Data cannot be shared publicly because of the matter about personal information. Data are available from the Kyushu University Institutional Review Board (ijkseimei@jimu.kyushu-u.ac.jp) on reasonable request.

Funding Statement

The author(s) received no specific funding for this work

References

  • 1.Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European. Eur Heart J. 2021;42:373–498. doi: 10.1093/eurheartj/ehaa612 [DOI] [PubMed] [Google Scholar]
  • 2.Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace. 2018;20:157–208. doi: 10.1093/europace/eux275 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Nogami A, Kurita T, Abe H, Ando K, Ishikawa T, Imai K, et al. JCS/JHRS 2019 Guideline on non-pharmacotherapy of cardiac arrhythmias. J Arrhythm. 2021;00:1–162 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Jilek C, Ullah W. Pulmonary vein reconnections or substrate in the left atrium: what is the reason for atrial fibrillation recurrences? A dialogue on a pressing clinical situation. Europace. 2019;21(Supplement_1):i12–i20. doi: 10.1093/europace/euy289 [DOI] [PubMed] [Google Scholar]
  • 5.Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372:1812–22. doi: 10.1056/NEJMoa1408288 [DOI] [PubMed] [Google Scholar]
  • 6.Sanders P, Hocini M, Jais P, Sacher F, Hsu LF, Takahashi Y, et al. Complete isolation of the pulmonary veins and posterior left atrium in chronic atrial fibrillation. Long-term clinical outcome. Eur Heart J. 2007;28:1862–71. doi: 10.1093/eurheartj/ehl548 [DOI] [PubMed] [Google Scholar]
  • 7.Dixit S, Marchlinski FE, Lin D, Callans DJ, Bala R, Riley MP, et al. Randomized ablation strategies for the treatment of persistent atrial fibrillation: RASTA study. Circ Arrhythm Electrophysiol 2012;5:287–94. doi: 10.1161/CIRCEP.111.966226 [DOI] [PubMed] [Google Scholar]
  • 8.Vogler J, Willems S, Sultan A, Schreiber D, Lüker J, Servatius H, et al. Pulmonary vein isolation versus defragmentation: the CHASE-AF clinical trial. J Am Coll Cardiol. 2015;66:2743–52. doi: 10.1016/j.jacc.2015.09.088 [DOI] [PubMed] [Google Scholar]
  • 9.Driessen AHG, Berger WR, Krul SPJ, van den Berg NWE, Neefs J, Piersma FR, et al. Ganglion plexus ablation in advanced atrial fibrillation: the AFACT study. J Am Coll Cardiol. 2016;68:1155–65. doi: 10.1016/j.jacc.2016.06.036 [DOI] [PubMed] [Google Scholar]
  • 10.Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S, et al. Tailored atrial substrate modification based on low-voltage areas in catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7:825–33. doi: 10.1161/CIRCEP.113.001251 [DOI] [PubMed] [Google Scholar]
  • 11.Takamiya T, Nitta J, Inaba O, Sato A, Inamura Y, Murata K, et al. Impact of diagnosis-to-ablation time on non-pulmonary vein triggers and ablation outcomes in persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2021;32:1251–1258. doi: 10.1111/jce.15002 [DOI] [PubMed] [Google Scholar]
  • 12.Tohoku S, Fukunaga M, Nagashima M, Korai K, Hirokami J, Yamamoto K, et al. Clinical impact of eliminating nonpulmonary vein triggers of atrial fibrillation and nonpulmonary vein premature atrial contractions at initial ablation for persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2021;32:224–234. doi: 10.1111/jce.14830 [DOI] [PubMed] [Google Scholar]
  • 13.Della Rocca DG, Tarantino N, Trivedi C, Mohanty S, Anannab A, Salwan AS, et al. Non-pulmonary vein triggers in nonparoxysmal atrial fibrillation: Implications of pathophysiology for catheter ablation. J Cardiovasc Electrophysiol. 2020;31:2154–2167. doi: 10.1111/jce.14638 [DOI] [PubMed] [Google Scholar]
  • 14.Gianni C, Mohanty S, Trivedi C, Di Biase L, Natale A. Novel concepts and approaches in ablation of atrial fibrillation: the role of non-pulmonary vein triggers. Europace. 2018;20:1566–1576. doi: 10.1093/europace/euy034 [DOI] [PubMed] [Google Scholar]
  • 15.Kawai S, Mukai Y, Inoue S, Yakabe D, Nagaoka K, Sakamoto K, et al. Non-pulmonary vein triggers of atrial fibrillation are likely to arise from low-voltage areas in the left atrium. Sci Rep. 2019;9:12271. doi: 10.1038/s41598-019-48669-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Santangeli P, Marchlinski FE. Techniques for the provocation, localization, and ablation of non-pulmonary vein triggers for atrial fibrillation. Heart Rhythm. 2017;14:1087–1096. doi: 10.1016/j.hrthm.2017.02.030 [DOI] [PubMed] [Google Scholar]
  • 17.Hayashi K, An Y, Nagashima M, Hiroshima K, Ohe M, Makihara Y, et al. Importance of nonpulmonary vein foci in catheter ablation for paroxysmal atrial fibrillation. Heart Rhythm. 2015;12:1918–24. doi: 10.1016/j.hrthm.2015.05.003 [DOI] [PubMed] [Google Scholar]
  • 18.Matsunaga-Lee Y, Egami Y, Matsumoto S, Masunaga N, Nakamura H, Matsuhiro Y, et al. Clinical impact of a self-reference mapping technique to detect non-pulmonary vein triggers: A multi-center study. Int J Cardiol. 2020;321:81–87. doi: 10.1016/j.ijcard.2020.08.015 [DOI] [PubMed] [Google Scholar]
  • 19.Sciarra L, Rebecchi M, De Ruvo E, De Luca L, Zuccaro LM, Fagagnini A, et al. How many atrial fibrillation ablation candidates have an underlying supraventricular tachycardia previously unknown? Efficacy of isolated triggering arrhythmia ablation. Europace. 2010;12:1707–12. doi: 10.1093/europace/euq327 [DOI] [PubMed] [Google Scholar]
  • 20.Inoue K, Sotomi Y, Masuda M, Furukawa Y, Hirata A, Egami Y, et al. Efficacy of extensive ablation for persistent atrial fibrillation with trigger-based vs. substrate-based mechanisms—A prespecified subanalysis of the EARNEST-PVI trial. Circ J. 2021. Mar 26. doi: 10.1253/circj.CJ-21-0126 [DOI] [PubMed] [Google Scholar]
  • 21.Takamiya T, Inaba O, Nitta J, Sato A, Inamura Y, Murata K, et al. Association between the locations of non-pulmonary vein triggers and ablation outcomes in repeat procedures after cryoballoon ablation of paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2020. Nov 6. doi: 10.1007/s10840-020-00913-9 [DOI] [PubMed] [Google Scholar]
  • 22.Rillo M, Palamà Z, Punzi R, Vitanza S, Aloisio A, Polini S, et al. A new interpretation of nonpulmonary vein substrates of the left atrium in patients with atrial fibrillation. J Arrhythm. 2021;37:338–47. doi: 10.1002/joa3.12521 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kato N, Nitta J, Sato A, Inamura Y, Takamiya T, Inaba O, et al. Characteristics of the nonpulmonary vein foci induced after second-generation cryoballoon ablation for paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2020;31:174–184. doi: 10.1111/jce.14314 [DOI] [PubMed] [Google Scholar]
  • 24.Santangeli P, Zado ES, Hutchinson MD, Riley MP, Lin D, Frankel DS, et al. Prevalence and distribution of focal triggers in persistent and long-standing persistent atrial fibrillation. Heart Rhythm. 2016;13:374–82. doi: 10.1016/j.hrthm.2015.10.023 [DOI] [PubMed] [Google Scholar]
  • 25.Kuroi A, Miyazaki S, Usui E, Ichihara N, Kanaji Y, Takagi T, et al. Adenosine-provoked atrial fibrillation originating from non-pulmonary vein foci: The clinical significance and outcome after catheter ablation. JACC Clin Electrophysiol. 2015;1:127–135. doi: 10.1016/j.jacep.2015.02.020 [DOI] [PubMed] [Google Scholar]
  • 26.Sakamoto Y, Osanai H, Hiramatsu S, Matsumoto H, Tagahara K, Hosono H, et al. Efficacy of isoproterenol in the evaluation of dormant conduction and arrhythmogenic foci identification in atrial fibrillation ablation. BMC Cardiovasc Disord. 2020;20:397. doi: 10.1186/s12872-020-01685-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Narui R, Matsuo S, Isogai R, Tokutake K, Yokoyama K, Kato M, et al. Impact of deep sedation on the electrophysiological behavior of pulmonary vein and non-PV firing during catheter ablation for atrial fibrillation. J Interv Card Electrophysiol. 2017;49:51–57. doi: 10.1007/s10840-017-0238-6 [DOI] [PubMed] [Google Scholar]
  • 28.Nakamaru R, Okada M, Tanaka N, Tanaka K, Ninomiya Y, Hirao Y, et al. Outcomes after atrial fibrillation ablation in patients with premature atrial contractions originating from non-pulmonary veins. JACC Clin Electrophysiol. 2019;5:1319–1327. doi: 10.1016/j.jacep.2019.08.002 [DOI] [PubMed] [Google Scholar]
  • 29.Kubala M, Lucena-Padros I, Xie S, Casado-Arroyo R, Frankel DS, Lin D, et al. P-wave morphology and multipolar intracardiac atrial activation to facilitate nonpulmonary vein trigger localization. J Cardiovasc Electrophysiol. 2019;30:865–876. doi: 10.1111/jce.13899 [DOI] [PubMed] [Google Scholar]
  • 30.Della Rocca DG, Mohanty S, Trivedi C, Di Biase L, Natale A. Percutaneous treatment of non-paroxysmal atrial fibrillation: A paradigm shift from pulmonary vein to non-pulmonary vein trigger ablation? Arrhythm Electrophysiol Rev. 2018;7:256–260. doi: 10.15420/aer.2018.56.2 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Luigi Sciarra

6 Dec 2021

PONE-D-21-34225Intra-atrial activation pattern is useful to localize the areas of non-pulmonary vein triggers of atrial fibrillationPLOS ONE

Dear Dr. Mukai,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

ACADEMIC EDITOR: Dear Authors, after a careful evaluation of your paper, according to our reviewers' suggestion, our opinion is that your manuscript cannot be accepted as it is, but it needs major revisions. In particular, some methodological issues needs to be better clarified. 

Please submit your revised manuscript by Jan 20 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Luigi Sciarra

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

Additional Editor Comments:

Dear Authors, after a careful evaluation of your paper, according to our reviewers' suggestion, our opinion is that your manuscript cannot be accepted as it is, but it needs major revisions.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The work is very interesting and well written.

I would discuss two aspects in depth:

1. Before the analysis of non-PV triggers, the importance of the electrophysiological study, especially in paroxysms without heart disease, should be highlighted in order to find any organized arrhythmias. Please read Sciarra L, Rebecchi M, De Ruvo E, De Luca L, Zuccaro LM, Fagagnini A, Corò L, Allocca G, Lioy E, Delise P, Calò L. How many atrial fibrillation ablation candidates have an underlying supraventricular tachycardia previously unknown? Efficacy of isolated triggering arrhythmia ablation. Europace. 2010 Dec;12(12):1707-12. doi: 10.1093/europace/euq327. Epub 2010 Sep 10. PMID: 20833693.

2. I would also briefly mention the role of the substrate as the islets of fibrosis in the left atrium (Rillo M, Palamà Z, Punzi R, Vitanza S, Aloisio A, Polini S, Tucci A, Pollastrelli A, Zonno F, Anastasia A, Giannattasio CF, My L. A new interpretation of nonpulmonary vein substrates of the left atrium in patients with atrial fibrillation. J Arrhythm. 2021 Feb 22;37(2):338-347. doi: 10.1002/joa3.12521. PMID: 33850575; PMCID: PMC8021999. )

Reviewer #2: Comments to the Author

This paper focused on the method to distinguish the areas of non-pulmonary vein triggers of AF with an electrode catheter.

I clinically agree with author’s ideas, but there are some major problems.

In particular, parts of the Methods section are considerably lacking.

Major comments

1. This CS catheter you recommend is generally difficult to use. Aren’t the electrode catheters over-used, such as the PentaRay or BeeAT catheter? Therefore, I think it is difficult to use this method as a standardized algorithm.

2. Although there is a description of 751 sessions, the total number of cases and paroxysmal and non-paroxysmal cases are unknown. This study is a retrospective study and more patient information should be provided.

3. Were the 35 cases in this study completely cured for the entire follow-up period by the focal ablation of the non-pulmonary vein origins? Did you try to re-induce AF after the ablation of the non-pulmonary vein origins? This study found that paroxysmal and non-paroxysmal non-pulmonary vein origins were approximately equal. Moreover, in the intracardiac electrocardiogram shown in Fig. 1B, the onset of the AF is far from the previous QRS. From the above, it is hard to believe that it was the correct site to prove the origin of AF. Finally, I consider it to have an overall low credibility.

4. There were too few cases of non-pulmonary vein origins in this study. The authors wrote that in the Discussion section, but you should strongly state it in the Limitations section. In addition, the number of PV origin cases should also be clearly written in the manuscript.

Reviewer #3: Authors presented an interesting paper focused on the research of non PV trigger areas in the setting of atrial fibrillation.

PVI was firstly performed and induction of AF was subsequently attempted to observe non PVI foci.

Some considerations:

- retrospective analysis is not the best way to investigate the issue (this concept has been underlined in limitations)

- The possibility to discover extra PV trigger for AF as been previously well described (How many atrial fibrillation ablation candidates have an underlying supraventricular tachycardia previously unknown? Efficacy of isolated triggering arrhythmia ablation. Sciarra L, Rebecchi M, De Ruvo E, De Luca L, Zuccaro LM, Fagagnini A, Corò L, Allocca G, Lioy E, Delise P, Calò L.

Europace. 2010 Dec;12(12):1707-12. doi: 10.1093/europace/euq327. Epub 2010 Sep 10). Why has been not a first research of triggers attempted? Please add a comment.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Antonio Scarà

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Apr 25;17(4):e0264894. doi: 10.1371/journal.pone.0264894.r002

Author response to Decision Letter 0


19 Jan 2022

Reviewer #1: The work is very interesting and well written.

Thank you for your general understanding to our work.

I would discuss two aspects in depth:

1. Before the analysis of non-PV triggers, the importance of the electrophysiological study, especially in paroxysms without heart disease, should be highlighted in order to find any organized arrhythmias. Please read Sciarra L, Rebecchi M, De Ruvo E, De Luca L, Zuccaro LM, Fagagnini A, Corò L, Allocca G, Lioy E, Delise P, Calò L. How many atrial fibrillation ablation candidates have an underlying supraventricular tachycardia previously unknown? Efficacy of isolated triggering arrhythmia ablation. Europace. 2010 Dec;12(12):1707-12. doi: 10.1093/europace/euq327. Epub 2010 Sep 10. PMID: 20833693.

We completely agree with the reviewer. We well consider that SVT can be a trigger of AF in some cases. In the enrolled patients in the present study, no SVTs were induced except 3 cavotricuspid isthmus (CTI)-dependent atrial flutters in EPS. Now this is mentioned in the Result section. We have also added the mentioned study as a reference. The analyzed non-PV triggers in this study were ectopic foci that initiate fibrillatory activities from the beginning.

(Results)

We considered supraventricular tachycardias (SVT) as possible triggers of AF as well [19]. CTI-dependent atrial flutters were induced during EPS in 3 cases, but no other SVTs were induced in the studied patients.

(References)

19. Sciarra L, Rebecchi M, De Ruvo E, De Luca L, Zuccaro LM, Fagagnini A, et al. How many atrial fibrillation ablation candidates have an underlying supraventricular tachycardia previously unknown? Efficacy of isolated triggering arrhythmia ablation. Europace. 2010;12:1707-12.

2. I would also briefly mention the role of the substrate as the islets of fibrosis in the left atrium (Rillo M, Palamà Z, Punzi R, Vitanza S, Aloisio A, Polini S, Tucci A, Pollastrelli A, Zonno F, Anastasia A, Giannattasio CF, My L. A new interpretation of nonpulmonary vein substrates of the left atrium in patients with atrial fibrillation. J Arrhythm. 2021 Feb 22;37(2):338-347. doi: 10.1002/joa3.12521. PMID: 33850575; PMCID: PMC8021999. )

We completely agree with the reviewer and we also strongly recognize the relationship between left atrial degeneration and arrhythmogenic substrate. It is a great theme whether to go with trigger mapping/ablation or substrate modification. In terms of AF trigger, we previously reported that non-PV AF trigger is likely to arise from degenerated atrial tissue where maintenance substrate of AF may co-exist. (reference #15)

Reviewer #2: Comments to the Author

This paper focused on the method to distinguish the areas of non-pulmonary vein triggers of AF with an electrode catheter.

I clinically agree with author’s ideas, but there are some major problems.

In particular, parts of the Methods section are considerably lacking.

We appreciate the reviewer’s general comment to our work. We would like to further explain our research design and what we would like to demonstrate. We considered the above-mentioned issues and revised the manuscript as below.

Major comments

1. This CS catheter you recommend is generally difficult to use. Aren’t the electrode catheters over-used, such as the PentaRay or BeeAT catheter? Therefore, I think it is difficult to use this method as a standardized algorithm.

As reviewer pointed out, the CS catheter (BeeAT) used in this study may not be available worldwide and we know that usable number of electrode is limited in some countries. What we intended to demonstrate in this study was that the basically-positioned catheters in the HRA and CS provide useful information to localize a non-PV trigger of AF and help further detailed mapping. Since we understand that our strategy cannot be universally recommended, we have revised and added sentences in Limitations section as below.

(Limitations)

From

Finally, the assessment of the intra-cardiac electrograms might be difficult soon after a defibrillation because it takes a few seconds for the baseline of electrograms to return to where it was.

To

Fourth, the assessment of the intra-cardiac electrograms might be difficult soon after a defibrillation because it takes a few seconds for the baseline of electrograms to return to where it was. Finally, the electrode catheter used in this study, which can simultaneously record CS and RA potentials (BeeAT), is not available worldwide and can only be used in limited regions. Therefore, it is necessary to verify whether the same results can be obtained using widely available separate CS and RA catheters.

2. Although there is a description of 751 sessions, the total number of cases and paroxysmal and non-paroxysmal cases are unknown. This study is a retrospective study and more patient information should be provided.

As the reviewer mentioned, the type of AF (paroxysmal and persistent) is very important in AF ablation studies. Therefore, the number of patients with paroxysmal and persistent AF and the number of non-PV triggers in all 751 sessions were added to the Methods as follows.

(Methods)

from

We retrospectively analyzed 37 non-PV triggers in 751 ablation sessions for symptomatic AF from January 2017 to December 2020.

To

We retrospectively analyzed 37 non-PV triggers in 751 ablation sessions for symptomatic AF (including 310 paroxysmal AF) from January 2017 to December 2020.

3. Were the 35 cases in this study completely cured for the entire follow-up period by the focal ablation of the non-pulmonary vein origins? Did you try to re-induce AF after the ablation of the non-pulmonary vein origins? This study found that paroxysmal and non-paroxysmal non-pulmonary vein origins were approximately equal. Moreover, in the intracardiac electrocardiogram shown in Fig. 1B, the onset of the AF is far from the previous QRS. From the above, it is hard to believe that it was the correct site to prove the origin of AF. Finally, I consider it to have an overall low credibility.

We appreciate the reviewer’s insightful comments. As for prognosis, we have previously reported that non-recurrence rate of successfully ablated non-PV trigger cases was comparable to those with no detectable non-PV triggers (reference #15). We would like the reviewer to understand that the present study is not a long-term outcome study but deals with a mapping methodology.

Yes. We re-induced AF after ablation to confirm the elimination of targeted non-PV triggers as stated in Methods. In order to certify the methodology, we added a sentence in Methods as follows.

(Methods)

AF induction test was repeated to see if there were any other non-PV triggers remaining.

In appreciation with the reviewer’s suggestion, we also have added sentences regarding the prevalence of non-PV triggers in patients with paroxysmal and non-paroxysmal AF respectively in the Discussion section as follows.

(Discussion)

The occurrence of non-PV triggers was comparable in paroxysmal (17 in 310, 5.5%) and in non-paroxysmal cases (18 in 441, 4.1%). The Prevalence of non-PV triggers was similar regardless of arrhythmia type, which is consistent to previous reports including ours [15, 23].

Finally, we would like to discuss the credibility of the non-PV mapping in Figure 1B. We would like to the reviewer to understand that Figure 1B is never showing an earliest activation electrogram but the measurement strategy in this study. As a note, coupling interval (CI) between the previous atrial potential and the ectopic beat potential recorded at the RA was 303 msec, which was not that long and the atrial activation showed so-called P on T. More than anything, the ectopic beat actually had initiated AF. We thus would like to ensure that atrial premature beat in Figure 1B is of an exact non-PV trigger.

4. There were too few cases of non-pulmonary vein origins in this study. The authors wrote that in the Discussion section, but you should strongly state it in the Limitations section. In addition, the number of PV origin cases should also be clearly written in the manuscript.

Thank you for this insightful comment. The incidence of non-PV triggers may be lower in this study than in some previous studies. However, please ensure that we just focused on atrial AF triggers and thus excluded SVC triggers in this study. Considering this, prevalence of non=PV triggers in this study is not that small. We think that SVC can be treatable in a preventive manner (as the 5th thoracic vein) and a SVC trigger is not difficult to map. What we intended to clarify was how to map an atrial trigger of AF. Prevalence of PV trigger in our EPS strategy is published in-detail in our previous study (refenrence #15). In this study, non-PV triggers were induced after completion of PVI as mentioned in Method. Therefore, non-PV triggers in the near PV antrum might have been eliminated by PVI. We now mentioned this point in Limitations.

(Limitations)

The low incidence in this study of non-PV triggers may be partly because we excluded SVC triggers in this study. Another reason may be because non-PV triggers were induced after completion of PVI in this study. Thus, non-PV triggers originating from near PV antrum might have been eliminated by PVI.

Reviewer #3: Authors presented an interesting paper focused on the research of non PV trigger areas in the setting of atrial fibrillation.

PVI was firstly performed and induction of AF was subsequently attempted to observe non PVI foci.

Thank you for your general understanding to our work.

Some considerations:

- retrospective analysis is not the best way to investigate the issue (this concept has been underlined in limitations)

As the reviewer mentioned, it is difficult to conclude only with a retrospective study. Therefore, we emphasized this point further in Limitations as below.

(Limitations)

From

First, this study was a retrospective study analyzing a limited sample size, therefore, a prospective study with more data is needed.

To

First, this study was a retrospective study analyzing a limited sample size, therefore, a prospective study with more data is needed to standardize this analysis method for clinical practice.

- The possibility to discover extra PV trigger for AF has been previously well described (How many atrial fibrillation ablation candidates have an underlying supraventricular tachycardia previously unknown? Efficacy of isolated triggering arrhythmia ablation. Sciarra L, Rebecchi M, De Ruvo E, De Luca L, Zuccaro LM, Fagagnini A, Corò L, Allocca G, Lioy E, Delise P, Calò L.

Europace. 2010 Dec;12(12):1707-12. doi: 10.1093/europace/euq327. Epub 2010 Sep 10). Why has been not a first research of triggers attempted? Please add a comment.

Thank you for this valuable comment. As the reviewer stated, SVT can be a cause of AF. If a SVT could be induced during AF ablation procedure and EPS, we would definitely map and ablate it, whereas there were no cases in which SVT (AVNRT, AVRT, FAT) was induced after PVI in the present study. As in previous studies, there is a strategy to perform EPS eliciting the cause of AF before PVI, however, in order to reduce the recurrence of AF as much as possible, EPS was performed after PVI, which is a standard treatment for AF in practice. We now added the following sentences to the Result section. We have also added the mentioned study as a reference.

(Results)

We considered supraventricular tachycardias (SVT) as possible triggers of AF as well [19]. Cavotricuspid isthmus-dependent atrial flutters were induced during EPS in 3 cases, but no other SVTs were induced in the studied patients.

(References)

19. Sciarra L, Rebecchi M, De Ruvo E, De Luca L, Zuccaro LM, Fagagnini A, et al. How many atrial fibrillation ablation candidates have an underlying supraventricular tachycardia previously unknown? Efficacy of isolated triggering arrhythmia ablation. Europace. 2010;12:1707-12.

Attachment

Submitted filename: renamed_75041.docx

Decision Letter 1

Luigi Sciarra

9 Feb 2022

PONE-D-21-34225R1Intra-atrial activation pattern is useful to localize the areas of non-pulmonary vein triggers of atrial fibrillationPLOS ONE

Dear Dr. Mukai,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Dear Authors, after a careful evaluation of your paper, our opinion is that the quality of your manuscript significantly improved. However one of our reviewers is still suggesting some revisions. Best regardsLuigi Sciarra==============================

Please submit your revised manuscript by Mar 26 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Luigi Sciarra

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

Dear Authors, after a careful evaluation of your paper, our opinion is that the quality of your manuscript significantly improved. However one of our reviewers is still suggesting some revisions. Best regards

Luigi Sciarra

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Point two on the role of extrapulmonary substrates has not been adequately investigated. I believe it is not possible to treat intra-atrial delays without talking about fibrosis!

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Zefferino Palamà

Reviewer #3: Yes: Antonio Scarà

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Apr 25;17(4):e0264894. doi: 10.1371/journal.pone.0264894.r004

Author response to Decision Letter 1


17 Feb 2022

Reviewer #1: Point two on the role of extrapulmonary substrates has not been adequately investigated. I believe it is not possible to treat intra-atrial delays without talking about fibrosis!

Thank you for your excellent comment again about the atrial fibrosis. To address the importance of the relationship between left atrial degeneration and arrhythmogenic substrate in AF ablation, the following sentence and the reference below were added in Discussion and Reference.

(Discussion)

For detailed mapping, it is also important to evaluate the substrate such as fibrosis by using multipolar electrodes [22].

(Reference)

22. Rillo M, Palamà Z, Punzi R, Vitanza S, Aloisio A, Polini S, et al. A new interpretation of nonpulmonary vein substrates of the left atrium in patients with atrial fibrillation. J Arrhythm. 2021;37:338-47.

Attachment

Submitted filename: renamed_2ca88.docx

Decision Letter 2

Luigi Sciarra

21 Feb 2022

Intra-atrial activation pattern is useful to localize the areas of non-pulmonary vein triggers of atrial fibrillation

PONE-D-21-34225R2

Dear Dr. Mukai,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Luigi Sciarra

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All queries have been properly addressed. The role of fibrosis in the genesis and maintenance of atrial fibrillation cannot be ignored

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Zefferino Palamà

Acceptance letter

Luigi Sciarra

13 Apr 2022

PONE-D-21-34225R2

Intra-atrial activation pattern is useful to localize the areas of non-pulmonary vein triggers of atrial fibrillation

Dear Dr. Mukai:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Luigi Sciarra

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: renamed_75041.docx

    Attachment

    Submitted filename: renamed_2ca88.docx

    Data Availability Statement

    Data cannot be shared publicly because of the matter about personal information. Data are available from the Kyushu University Institutional Review Board (ijkseimei@jimu.kyushu-u.ac.jp) on reasonable request.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES